• Homepage
• About us
• Our Partners
• Research database
• Workshops
• Newsletters and resources
• Videos and Animations
• International Conferences
• Funding opportunities
• Search

I am working on a project funded by Children with Cancer UK for convection enhanced delivery of various nanoplatforms of a novel temozolomide analogue (N3-propargyl) in resistant high grade children gliomas. We have developed three distinct nanoconstructs including N3-sulfobutyl ether β-cyclodextrin (SBE-β-CD) inclusion nanocomplex, N3-loaded apoferritin nanocage, and N3-SBE-β-CD-loaded nanoliposomes) and currently evaluating their pharmacokinetic, distribution and efficacy studies in rats. My research focuses on smart nanocarriers to enhance the efficacy and minimize side effects of cancer chemotherapeutics.

Existing collaborations relevant to drug delivery

N/A

Publications relevant to drug delivery

Jafari I, Heravi Shargh V, Shahriari M, Abbasi A, Jaafari MR, Khamesipour A, Badiee A. Cationic liposome formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model. Immunobiology. 2018;223(6-7):493-500

Heravi Shargh V, Hondermarck H, Liang M. Gelatin–albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy. Nanomedicine (Lond). 2017;12(9):977-89. 

Heravi Shargh V, Hondermarck H, Liang M. Albumin Hybrid Nanoparticles Loaded with Tyrosine Kinase Inhibitor GNF-5837 for Targeted Inhibition of Breast Cancer Cell Growth and Invasion. Int J Pharm. 2016;515(1-2):527-34

Heravi Shargh V, Hondermarck H, Liang M. Antibody-targeted biodegradable nanoparticles for cancer therapy. Nanomedicine (Lond). 2016;11(1):63-79.